Total Payments
$122,388
2024 Payments
$1,472
Companies
48
Transactions
298
Medicare Patients
5,740
Medicare Billing
$1.7M
Payment Breakdown by Category
Consulting$68,486 (56.0%)
Other$39,024 (31.9%)
Food & Beverage$7,443 (6.1%)
Travel$6,982 (5.7%)
Education$262.66 (0.2%)
Research$190.25 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $68,486 | 18 | 56.0% |
| Honoraria | $38,800 | 31 | 31.7% |
| Food and Beverage | $7,443 | 210 | 6.1% |
| Travel and Lodging | $6,982 | 19 | 5.7% |
| Education | $262.66 | 11 | 0.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $224.00 | 2 | 0.2% |
| Unspecified | $190.25 | 7 | 0.2% |
Payments by Type
General
$122,198
291 transactions
Research
$190.25
1 transactions
Ownership
$0
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Daiichi Sankyo Inc. | $68,121 | 51 | $0 (2024) |
| Cornerstone Specialty Network LLC | $42,609 | 47 | $0 (2024) |
| Heron Therapeutics, Inc. | $6,494 | 4 | $0 (2017) |
| Merck Sharp & Dohme LLC | $473.17 | 15 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $450.34 | 15 | $0 (2024) |
| Foundation Medicine, Inc. | $412.93 | 2 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $313.50 | 19 | $0 (2024) |
| Seagen Inc. | $255.95 | 10 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $237.75 | 15 | $0 (2024) |
| Amgen Inc. | $221.73 | 12 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,472 | 42 | Cornerstone Specialty Network LLC ($400.00) |
| 2023 | $37,061 | 66 | Daiichi Sankyo Inc. ($21,097) |
| 2022 | $16,794 | 48 | Cornerstone Specialty Network LLC ($15,019) |
| 2021 | $5,194 | 26 | Cornerstone Specialty Network LLC ($3,900) |
| 2020 | $49,485 | 25 | Daiichi Sankyo Inc. ($44,815) |
| 2019 | $4,344 | 24 | Cornerstone Specialty Network LLC ($3,528) |
| 2018 | $975.59 | 36 | Eli Lilly and Company ($190.25) |
| 2017 | $7,062 | 31 | Heron Therapeutics, Inc. ($6,494) |
All Payment Transactions
298 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $32.73 | General |
| Category: Genetically Defined Disease | ||||||
| 12/20/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $24.92 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $18.81 | General |
| 12/06/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $29.00 | General |
| Category: Hematology/Oncology | ||||||
| 12/05/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $92.62 | General |
| Category: NONE | ||||||
| 11/26/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $12.33 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $15.85 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Amneal Pharmaceuticals LLC | AVASTIN (Drug) | Food and Beverage | In-kind items and services | $14.65 | General |
| Category: ONCOLOGY | ||||||
| 10/11/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $27.62 | General |
| Category: Oncology | ||||||
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $22.91 | General |
| 09/20/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.43 | General |
| 09/13/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $34.99 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 09/06/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: Oncology | ||||||
| 08/24/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $117.65 | General |
| Category: Oncology | ||||||
| 08/23/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $9.73 | General |
| Category: Oncology | ||||||
| 08/15/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Education | In-kind items and services | $17.02 | General |
| Category: ONCOLOGY | ||||||
| 08/14/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $16.38 | General |
| Category: ONCOLOGY | ||||||
| 08/09/2024 | Bayer Healthcare Pharmaceuticals Inc. | Xofigo (Drug) | Food and Beverage | In-kind items and services | $16.61 | General |
| Category: Oncology | ||||||
| 07/29/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Education | In-kind items and services | $17.02 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2024 | GENZYME CORPORATION | ENJAYMO (Biological) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: Hematology | ||||||
| 07/19/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $21.07 | General |
| Category: Oncology | ||||||
| 07/18/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $36.49 | General |
| 07/18/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $10.84 | General |
| 07/17/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: ONCOLOGY | ||||||
| 06/14/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $14.21 | General |
| Category: CELLT | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH PEMBROLIZUMAB VS. PEMBROLIZUMAB ALONE AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE HIGH PD-L1 EXPRESSION | Eli Lilly and Company | $190.25 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 30 | 1,312 | 37,917 | $598,148 | $230,050 |
| 2022 | 30 | 1,333 | 34,082 | $568,275 | $245,895 |
| 2021 | 34 | 1,447 | 36,971 | $916,588 | $355,039 |
| 2020 | 38 | 1,648 | 58,210 | $2.1M | $854,864 |
Total Patients
5,740
Total Services
167,180
Medicare Billing
$1.7M
Procedure Codes
139
All Medicare Procedures & Services
139 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 20 | 3,180 | $104,640 | $57,989 | 55.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 181 | 395 | $83,006 | $35,596 | 42.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 285 | 438 | $62,070 | $26,627 | 42.9% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 23 | 28,500 | $80,250 | $25,087 | 31.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 55 | 193 | $48,829 | $17,848 | 36.6% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 17 | 2,420 | $60,500 | $13,520 | 22.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 37 | 52 | $14,760 | $6,936 | 47.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 56 | 120 | $15,600 | $5,456 | 35.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 47 | 47 | $15,045 | $5,204 | 34.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 31 | 31 | $12,493 | $5,103 | 40.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 36 | 66 | $16,930 | $4,864 | 28.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 65 | 85 | $15,300 | $4,099 | 26.8% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 13 | 78 | $10,920 | $3,897 | 35.7% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 48 | 149 | $8,642 | $3,069 | 35.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 79 | 243 | $11,664 | $2,433 | 20.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 18 | 50 | $5,850 | $2,325 | 39.7% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 19 | 111 | $3,996 | $1,657 | 41.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 20 | $2,942 | $1,218 | 41.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 13 | 58 | $3,132 | $1,211 | 38.7% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 13 | 46 | $4,922 | $1,101 | 22.4% |
| 96523 | Irrigation of implanted venous access drug delivery device | Office | 2023 | 24 | 60 | $2,760 | $882.02 | 32.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 17 | 17 | $2,397 | $875.30 | 36.5% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 14 | 17 | $1,342 | $652.18 | 48.6% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 24 | 53 | $2,226 | $597.43 | 26.8% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 13 | 59 | $1,711 | $558.03 | 32.6% |
About Dr. Rex Mowat, MD
Dr. Rex Mowat, MD is a Hematology & Oncology healthcare provider based in Toledo, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1346247251.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rex Mowat, MD has received a total of $122,388 in payments from pharmaceutical and medical device companies, with $1,472 received in 2024. These payments were reported across 298 transactions from 48 companies. The most common payment nature is "Consulting Fee" ($68,486).
As a Medicare-enrolled provider, Mowat has provided services to 5,740 Medicare beneficiaries, totaling 167,180 services with total Medicare billing of $1.7M. Data is available for 4 years (2020–2023), covering 139 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Toledo, OH
- Active Since 07/07/2005
- Last Updated 02/05/2026
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1346247251
Products in Payments
- Enhertu (Drug) $66,913
- SUSTOL (Drug) $6,494
- ENHERTU (Drug) $1,126
- KEYTRUDA (Biological) $444.91
- FOUNDATIONACT (Device) $300.00
- TUKYSA (Drug) $179.18
- TAGRISSO (Drug) $144.68
- Perjeta (Biological) $124.45
- Epkinly (Drug) $117.65
- FOUNDATIONONE (Device) $112.93
- IMBRUVICA (Drug) $99.81
- OPDIVO (Biological) $98.22
- CALQUENCE (Drug) $94.99
- XT CDX (Device) $92.62
- Doptelet (Drug) $92.42
- ERLEADA (Drug) $87.56
- SOMATULINE DEPOT (Drug) $75.29
- PROMACTA (Drug) $75.21
- ZYTIGA (Drug) $74.99
- SARCLISA (Biological) $74.79
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Toledo
Ahmad Zarzour, M.d, M.D
Hematology & Oncology — Payments: $23,407
Hematology & Oncology $23,407
Dr. David Brown, Md, MD
Hematology & Oncology — Payments: $2,105
Hematology & Oncology $2,105
Dr. Mohammad Rashid, Md, MD
Hematology & Oncology — Payments: $1,985
Hematology & Oncology $1,985
Dr. Danae Hamouda, M.d, M.D
Hematology & Oncology — Payments: $1,239
Hematology & Oncology $1,239
Timothy Kasunic, Md, MD
Hematology & Oncology — Payments: $956.37
Hematology & Oncology $956.37
Abhay Shelke, Md, MD
Hematology & Oncology — Payments: $665.04
Hematology & Oncology $665.04